Vaxcyte Inc Crosses Down 5-Day SMA Amid Market Declines
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 01 Dec 25
Source: Coinmarketcap
Vaxcyte Inc's stock dropped by 8.27% today, crossing down the 5-day SMA. This decline reflects a broader bearish sentiment in the market, with the Nasdaq-100 down 0.46% and the S&P 500 down 0.57%.\n\nThe overall market sentiment has been negative, influenced by concerns surrounding vaccine shares after a FDA official linked COVID-19 mRNA vaccines to heart issues in young men. This has led to increased scrutiny and selling pressure on related stocks.\n\nAs the market continues to react to these developments, Vaxcyte Inc's performance may be impacted by ongoing public concerns regarding vaccine safety and regulatory scrutiny.
Analyst Views on PCVX
Wall Street analysts forecast PCVX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PCVX is 104.80 USD with a low forecast of 50.00 USD and a high forecast of 163.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Analyst Rating
6 Buy
0 Hold
0 Sell
Strong Buy
Current: 51.370
Low
50.00
Averages
104.80
High
163.00
Current: 51.370
Low
50.00
Averages
104.80
High
163.00
About PCVX
Vaxcyte Inc. is a clinical-stage vaccine innovation company. The Company is engaged in developing spectrum conjugate and protein vaccines to prevent or treat bacterial infectious diseases. Its pipeline includes VAX-31, a 31-valent PCV candidate advancing to a Phase III adult clinical program and being evaluated in a Phase II infant clinical program, which is being developed for the prevention of invasive pneumococcal disease (IPD) in adults and infants and is the broadest-spectrum pneumococcal conjugate vaccine (PCV) candidate in the clinic. VAX-24, the Company’s 24-valent PCV candidate, is designed to cover more serotypes than any infant PCV on-market and is being evaluated in a Phase II infant study. Its pipeline also includes VAX-A1, a prophylactic vaccine candidate designed to prevent Group A Strep infections; VAX-PG, a therapeutic vaccine candidate designed to slow or stop the progression of periodontal disease; and VAX-GI, a vaccine candidate designed to prevent Shigella.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
